SCHEMBL6433651

SCHEMBL6433651

CC(C)(C)OC(=O)CNc1ccccc1C(=O)c1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.38
PTGES O14684 1/20 0.36
PTPRC P08575 2/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
AGTR1 P30556 1/20 0.34
MAPK8 P45983 2/20 0.34
DGAT2 Q96PD7 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
GABRA5 P31644 1/20 0.34
NPC1 O15118 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
PLG P00747 1/20 0.33
PLAU P00749 1/20 0.33
CTNNB1 P35222 1/20 0.32
TCF7L2 Q9NQB0 1/20 0.32
MAPK10 P53779 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433871 0.87 MAPK8 (0.38) CCNT1PTGESPTPRCMEN1KMT2A
SCHEMBL7403971 0.85 AGTR1 (0.39) MEN1KMT2AAGTR1NPC1PLG
SCHEMBL6434389 0.80 PTPRC (0.49) CCNT1PTPRCMEN1KMT2ADGAT2
SCHEMBL7860463 0.76 KDM4E (0.49) PTPRCMEN1KMT2AAGTR1ADRA1A
SCHEMBL6436909 0.74 DGAT2 (0.50) PTPRCMEN1KMT2ADGAT2ALDH1A1
SCHEMBL7371013 0.73 AGTR1 (0.32) CCNT1PTGESPTPRCMEN1KMT2A
SCHEMBL6433655 0.73 ALDH1A1 (0.40) MEN1KMT2APLAUALDH1A1MAPT
SCHEMBL6433264 0.72 ROCK2 (0.44) GAA
SCHEMBL7397677 0.72 PLK1 (0.35) MEN1KMT2AAGTR1MAPK8ADRA1A
SCHEMBL6436403 0.72 PLAU (0.52) NPC1PLGPLAUALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CCNT1 886/4885PTGES 728/4885PTPRC 1138/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CCNT1 886/4885PTGES 728/4885PTPRC 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.